evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

204 questions · 205 findings · 17 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 69 · 33.7%GRADE not reported 9 · 4.4%Very low 29 · 14.1%Low 36 · 17.6%Moderate 50 · 24.4%High 12 · 5.9%

Summary of findings: aztreonam lysine for inhalation vs tobramycin

Adverse events: number of treatment‐related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: aztreonam lysine for inhalation probably leads to higher adverse events: number of treatment‐related adverse events compared with tobramycin (moderate certainty).

1 finding from 1 review

Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin

Number experiencing adverse effects · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: amikacin liposome inhalation suspension (ALIS) showed no clear difference in adverse events: number of participants experiencing any TEAE compared with tobramycin (moderate certainty).

1 finding from 1 review

Summary of findings: levofloxacin for inhalation solution vs tobramycin

Pulmonary exacerbations: number of hospitalisations due to respiratory exacerbations · adults and children aged over 12 with CF and P aeruginosa

Summary of findings: levofloxacin for inhalation solution leads to lower pulmonary exacerbations: number of hospitalisations due to… compared with tobramycin (high certainty).

1 finding from 1 review

Summary of findings: anti‐pseudomonal antibiotics vs placebo

Survival: number of deaths · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: anti‐pseudomonal antibiotics showed no clear difference in survival: number of deaths compared with placebo (low certainty).

1 finding from 1 review

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

Pulmonary exacerbations: rate of PDEs per participant year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in pulmonary exacerbations: rate of PDEs per participant year compared with continuous cycles alternating placebo with tobramycin (low certainty).

1 finding from 1 review